HFI-419 is a potent inhibitor of insulin-regulated aminopeptidase (IRAP) with a K i value of 0.48 μM. It is utilized in research pertaining to cognitive and memory impairments, including Alzheimer's disease, brain trauma, and stroke [1].

HFI-419 inhibits IRAP with a K i value of 0.48 μM [1]. HFI-419 (1 μM) shows rapid disappearance that is associated with nonenzymatic (such as amide hydrolysis) processes [1].

HFI-419 (i.v, i.p; 2, 10 mg/kg) exhibits brain exposure and also exhibits potent inhibition of IRAP [1]. Animal Model: Sprague-Dawley rats [1] Dosage: 2 mg/kg, 10 mg/kg Administration: Intravenous, intraperitoneal Result: Exhibited a short apparent elimination half-life, a high plasma clearance and a large volume of distribution. Extended the apparent half-life to 4.6 h.